OBJECTIVE: To determine the cytotoxic activity of gemcitabine on a panel of endometrial cancer cell lines and to determine if the addition of platinum agents enhanced this activity. METHODS: A panel of four endometrial carcinoma cell lines was treated with variable concentrations of gemcitabine, gemcitabine and cisplatin, or gemcitabine and carboplatin. 3-(4,5-Cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays were performed to determine the IC(50). RESULTS: Each cell line evaluated revealed a dose-dependent decrease in cell growth for gemcitabine alone and in combination with platinum agents. The IC(50) of gemcitabine with cisplatin was significantly lower than that of gemcitabine alone for all cell lines, including the platinum-resistant line. CONCLUSION: Gemcitabine exerts in vitro cytotoxicity on endometrial cancer cell lines, and the combination of gemcitabine and cisplatin is superior to gemcitabine alone. This may represent a promising option for treatment of endometrial cancer.
OBJECTIVE: To determine the cytotoxic activity of gemcitabine on a panel of endometrial cancer cell lines and to determine if the addition of platinum agents enhanced this activity. METHODS: A panel of four endometrial carcinoma cell lines was treated with variable concentrations of gemcitabine, gemcitabine and cisplatin, or gemcitabine and carboplatin. 3-(4,5-Cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays were performed to determine the IC(50). RESULTS: Each cell line evaluated revealed a dose-dependent decrease in cell growth for gemcitabine alone and in combination with platinum agents. The IC(50) of gemcitabine with cisplatin was significantly lower than that of gemcitabine alone for all cell lines, including the platinum-resistant line. CONCLUSION:Gemcitabine exerts in vitro cytotoxicity on endometrial cancer cell lines, and the combination of gemcitabine and cisplatin is superior to gemcitabine alone. This may represent a promising option for treatment of endometrial cancer.
Authors: Jubilee Brown; Judith A Smith; Lois M Ramondetta; Anil K Sood; Pedro T Ramirez; Robert L Coleman; Charles F Levenback; Mark F Munsell; Maria Jung; Judith K Wolf Journal: Cancer Date: 2010-11-01 Impact factor: 6.860
Authors: Martee L Hensley; Don Dizon; Felicia Derosa; Ennapadam Venkatraman; Paul Sabbatini; Dennis S Chi; Jakob Dupont; A Dimitrios Colevas; David Spriggs; Carol Aghajanian Journal: Invest New Drugs Date: 2007-03-16 Impact factor: 3.850
Authors: Lata Mathew; Maryam Burney; Anjali Gaikwad; Pranavand Nyshadham; Elizabeth K Nugent; Anneliese Gonzalez; Judith A Smith Journal: Integr Cancer Ther Date: 2016-12-21 Impact factor: 3.279
Authors: Yanfang Li; Tao Liu; Cristina Ivan; Jie Huang; De-Yu Shen; John J Kavanagh; Robert C Bast; Siqing Fu; Wei Hu; Anil K Sood Journal: Front Oncol Date: 2013-03-20 Impact factor: 6.244
Authors: Tran N Le; Rachel E Harvey; Christine K Kim; Jubilee Brown; Robert L Coleman; Judith A Smith Journal: Gynecol Oncol Res Pract Date: 2017-11-14